Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Date publication

avril 2017

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis

Tous les auteurs :
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28379796

Résumé

High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of transplantation.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Bortezomib, administration & dosage, Combined Modality Therapy, Dexamethasone, administration & dosage, Disease-Free Survival, Female, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma, drug therapy, Salvage Therapy, Stem Cell Transplantation, Thalidomide, administration & dosage, Transplantation, Autologous

Référence

N. Engl. J. Med.. 2017 04;376(14):1311-1320